MOSCOW (MRC) -- Bayer has announced midterm targets covering margin- and sales growth for 2022-24. The company announced the targets at its virtual capital markets day on 10 March, said Chemweek.
Bayer is aiming for group net sales of EUR43.0-45.0 billion by 2024, up from EUR41.4 billion in 2020. The Crop Science division is projected to grow at a currency- and portfolio-adjusted rate of 3-5% annually from 2022 through 2024, faster than the market. Crop Science is targeting an EBITDA margin before special items of 27-29% by 2024, up from 24% in 2020 on further efficiency improvements.
Bayer expects its sales growth to regain momentum in 2021 and accelerate in subsequent years. The company says it is taking steps to strengthen revenue growth, profitability, and cash flow, and says that all three of its divisions “are projected to contribute to the company’s success in the coming years.” Werner Baumann, CEO of Bayer, said during the capital markets day that the company is aiming for above-market growth from 2022 for the Crop Science and consumer health divisions.
Sales of the consumer health division are also projected to increase annually by 3-5% at a currency- and portfolio-adjusted rate, with the division set to gain further market share, Bayer says. “The primary goal now for consumer health is to consolidate the substantial growth and margin improvements seen over the past 18 months,” Baumann said. Leading innovation and strong brands, a further digitalization of the business, and potentially also bolt-on acquisitions are expected to drive the growth of the business, Bayer says. The division's EBITDA margin before special items is expected to increase toward a mid-20s percentage from 22% in 2020, the company says.
Meanwhile, Bayer plans “to continue to grow at pharmaceuticals despite patent expirations and only expects to register a modest decline in sales in 2024,” Baumann says. The pharma division is expected to post annual sales growth of 3-5% at a currency- and portfolio-adjusted rate, through 2023. In 2024, Bayer anticipates a low- to mid-single digit percentage decline due to the patent expirations, with pharma set to return to sustainable growth in 2025. The division is expected to generate an EBITDA margin before special items of 32.0-34.0% through 2023, down from 34.9% in 2020, and remain above 30% even in 2024 despite the effect of the patent expirations, Bayer says.
The restructuring program Bayer announced in September 2020 will also help strengthen the company’s earnings power. “We aim to become an even simpler, leaner, and more flexible company,” said Wolfgang Nickl, CFO at Bayer. “In doing so, we are freeing up additional resources to invest in innovation and growth, enabling us to further strengthen profitability.” The program is expected to deliver annualized savings of more than EUR1.5 billion from 2024.
Nickl says that the company’s capital-allocation priorities include deleveraging its balance sheet after anticipated US litigation payouts; using a significant portion of its capital for dividends, maintaining its dividend policy and planning to pay out 30-40% of core earnings per share; and investing further resources in bolt-on acquisitions, especially at the pharma and consumer-health businesses. Net financial debt is projected to drop to EUR28-30 billion by the end of 2024, from EUR30 billion at the end of 2020 disregarding potential divestment proceeds, Bayer says.
As MRC reported earlier, Covestro closed the sale of its European polycarbonates (PC) sheets business to the Munich-based Serafin Group effective January 2, 2020. This includes key management and sales functions throughout Europe as well as production sites in Belgium and Italy.
Covestro (formerly Bayer MaterialScience) is an independent subgroup within Bayer. It was created as part of the restructuring of Bayer AG from the former business group Bayer Polymers, with certain of its activities being spun off to Lanxess AG. Covestro manufactures and develops materials such as coatings, adhesives and sealants, polycarbonates (CDs, DVDs), polyurethanes (automotive seating, insulation for refrigerating appliances) etc.
According to MRC's ScanPlast report, Russia's estimated consumption of PC granules (excluding imports and exports to\\from Belarus) rose in January-November 2020 by 18% year on year to 83,600 tonnes (70,600 tonnes a year earlier).
MRC